They are: BMI 35 or higher (no additional condition required) BMI 30 to 34.9 with heart failure, uncontrolled hypertension, or chronic kidney disease BMI 27 to 29.9 with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease Our Medicare GLP-1 Bridge eligibility tiers post covers each tier in detail, including the documentation the central processor will look for
Similarly, another phase 2 trial in subjects with obesity but no T2D examined doses of 1.0 mg, 3.0 mg, 4.5 mg, and 6.0 mg over 24 weeks
Whilst we did not find this replicated in our meta-analysis in this particular brain region (nor in any of the individual studies included), nonetheless we did find this difference in the occipital region
Your clinician can help you determine which form and route of administration best fit your goals and dosing schedule
Real world scenarios and examples Scenario One: A healthy 42 year old wants modest body composition changes